Literature DB >> 2887326

Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

A E Balant-Gorgia, L Balant.   

Abstract

Antipsychotic drugs (neuroleptics) are candidates for plasma concentration monitoring, but not all agents have the same potential in this respect. The present review analyses the available data on the kinetics and metabolism of fluphenazine, perphenazine, thiothixene, flupenthixol, clopenthixol, haloperidol, pimozide, penfluridol, sulpiride and clozapine. Although some of the drugs described in this review have been in use for many years, knowledge of their pharmacokinetics is still only approximate. This is primarily because determination in biological fluids is not always feasible. Accordingly, analytical methods useful for pharmacokinetic studies or plasma concentration monitoring of these antipsychotic drugs are discussed. With the exception of sulpiride, all the neuroleptics reviewed share some basic pharmacokinetic properties: good gastrointestinal absorption but reduced systemic availability because of hepatic first-pass metabolism, high hepatic clearance and a large apparent volume of distribution leading to an apparent elimination half-life of about 24 hours for most of these compounds. The renal elimination is negligible and it seems that these drugs do not possess active metabolites. The pharmacokinetic properties of antipsychotic drugs are important for the inclusion of a set of drugs in a psychiatric institution where there is a possibility of drug concentration monitoring. In addition, the availability of a depot preparation is of importance. These factors are discussed in view of the experience made during the last years in the University Psychiatric Institutions of Geneva.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887326     DOI: 10.2165/00003088-198713020-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  113 in total

1.  Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.

Authors:  L F Gram; K Overo; L Kirk
Journal:  Am J Psychiatry       Date:  1974-08       Impact factor: 18.112

2.  Effects of carbamazepine on plasma haloperidol levels.

Authors:  M W Jann; L Ereshefsky; S R Saklad; D R Seidel; C M Davis; N R Burch; C L Bowden
Journal:  J Clin Psychopharmacol       Date:  1985-04       Impact factor: 3.153

3.  Comparative determination of flupentixol in plasma by gas chromatography and radioimmunoassay in schizophrenic patients.

Authors:  A E Balant-Gorgia; L P Balant; C Genet; R Eisele
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

4.  Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients.

Authors:  C B Schaffer; A Shahid; J I Javaid; M W Dysken; J M Davis
Journal:  J Clin Psychopharmacol       Date:  1982-08       Impact factor: 3.153

5.  Plasma-fluphenazine concentrations after injection of long-acting esters.

Authors:  S H Curry; R Whelpton; P J de Schepper; S Vranckx; A A Schiff
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

6.  Determination of perphenazine and its sulphoxide metabolite in human plasma after therapeutic doses by gas chromatography.

Authors:  N E Larsen; J Naestoft
Journal:  J Chromatogr       Date:  1975-06-18

Review 7.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

8.  Influence of route of administration on haloperidol plasma levels in psychotic patients.

Authors:  G Bianchetti; E Zarifian; M F Poirier-Littre; P L Morselli; P Deniker
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-07

9.  Fluphenazine pharmacokinetics and therapeutic response.

Authors:  M W Dysken; J I Javaid; S S Chang; C Schaffer; A Shahid; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Stereoselective disposition of flupentixol: influence on steady-state plasma concentrations in schizophrenic patients.

Authors:  A E Balant-Gorgia; L P Balant; M Gex-Fabry; C Genet
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

View more
  9 in total

Review 1.  Prodrugs for the improvement of drug absorption via different routes of administration.

Authors:  L P Balant; E Doelker; P Buri
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Formation of active metabolites of psychotropic drugs. An updated review of their significance.

Authors:  S Caccia; S Garattini
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

4.  A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics.

Authors:  Gianluigi Tanda; Valentina Valentini; Maria Antonietta De Luca; Valentina Perra; Gian Pietro Serra; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

5.  Debrisoquine oxidation phenotype during neuroleptic monotherapy.

Authors:  E Spina; C Martines; A P Caputi; J Cobaleda; B Piñas; J A Carrillo; J Benitez
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  Biotransformation of post-clozapine antipsychotics: pharmacological implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 7.  The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Authors:  S Ulrich; C Wurthmann; M Brosz; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

Review 8.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

Review 9.  Pharmacokinetic optimisation of the treatment of psychosis.

Authors:  A E Balant-Gorgia; L P Balant; A Andreoli
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.